• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 15.4MATCH

MATCHClopidogrel + aspirinClopidogrel + placeboSize effect
Life-threatening bleedings*2.6%1.3%RR 1.26
95% CI (0.64–1.88)
p<0.0001
Major bleedings2%1%RR 1.36
95% CI (0.86–1.86)
p<0.0001
Minor bleedings3%1%p<0.0001
*

Life-threatening events were more frequent in the aspirin plus clopidogrel versus clopidogrel monotherapy, irrespective of whether they were GI (1.4 vs 0.6%) or intracranial (1.1 vs 0.7%)

Life-threatening events were more frequent in the aspirin plus clopidogrel versus clopidogrel monotherapy, irrespective of whether they were GI (1.4 vs 0.6%) or intracranial (1.1 vs 0.7%)

From: 15, Antithrombotic therapy

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.